JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy
We have successfully developed JUST-AAV, a novel AAV vector platform technology designed to enhance targeted delivery and reduce liver tropism, thereby improving safety and efficacy of AAV-based gene delivery technologies to the CNS. JUST-AAV encompasses a range of vector types optimized for various target tissues, including liver-sparing, muscle-targeting, and brain-targeting variants. This proprietary technology holds significant promise for advancing the field of AAV-based gene therapy.
'These findings represent a significant advancement toward new treatments for previously challenging CNS diseases,' said Hiroyuki Sonoda, Ph.D., Director, Senior Managing Executive Officer, and Executive Director, Research Division at JCR Pharmaceuticals. 'Our preclinical data demonstrate that our brain-targeting JUST-AAV technology delivers therapeutic agents to the central nervous system far more efficiently than conventional AAV9, while significantly reducing liver accumulation. This enhanced safety profile greatly increases the potential for clinical translation. This research is a crucial step in our ongoing commitment to developing innovative solutions for unmet medical needs.'
JCR showcased the following presentation:
Incorporation of transferrin receptor binder and surface mutations into AAV enables efficient brain delivery and reduced liver tropism
Presenter: Yuhei Ashida (JCR Pharmaceuticals)
Researchers successfully created a brain-targeting AAV vector (brain-targeting JUST-AAV) by incorporating a miniaturized antibody that binds to the transferrin receptor, into the AAV capsid. Furthermore, unique modifications to the AAV capsid sequence significantly reduced AAV vector accumulation in the liver, a known source of adverse effects. In mouse studies, the JUST-AAV vector achieved 77-fold higher expression of green fluorescent protein (GFP) in the brain compared to AAV9, while reducing the tropism to the liver by 99%. To further enhance brain targeting and BBB permeability, the researchers incorporated additional molecules that bind to receptors other than the transferrin receptor into the AAV capsid. In monkey studies, this bispecific vector demonstrated an improved gene delivery efficiency to the brain by several orders of magnitude compared with AAV9, while reducing infection in potentially problematic tissues such as the liver and dorsal root ganglia by more than 90%.
Application of JUST-AAV to a mouse model of neuronal ceroid lipofuscinosis resulted in the disappearance of symptoms such as seizures and prolonged lifespan to an extent of a functional cure. These results suggest that the newly developed JUST-AAV technology offers the potential for safer and more efficient gene therapy than conventional gene delivery vectors.
About the American Society of Gene and Cell Therapy (ASGCT)
The American Society of Gene and Cell Therapy (ASGCT) is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. The mission of the ASGCT is to advance knowledge, awareness, and education, leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. For more information, please visit www. asgct.org.
About the J-Brain Cargo ® Platform Technology
JCR Pharmaceuticals has developed a proprietary blood-brain barrier (BBB)-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system (CNS). The first drug developed based on this technology is IZCARGO ® (INN: pabinafusp alfa) and was approved in Japan for the treatment of a lysosomal storage disorder.
JUST-AAV
JUST-AAV is a proprietary platform technology that utilizes modified adeno-associated virus (AAV) vectors. The technology entails insertion of miniaturized antibodies against receptors on selected tissues, organs or the blood-brain barrier onto the capsid surface, enhancing targeted delivery to those tissues and organs. Further capsid modifications minimize off-target effects and improve safety. The name is derived from ' J CR' ' U ltimate destination of organ' ' S afeguarding against off-target delivery' and ' T ransformative technology' reflecting its potential for broad application across various diseases.
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/index.html.
Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as 'believe,' 'estimate,' 'anticipate,' 'intend,' 'plan,' 'will,' 'would,' 'target' and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.
This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.
Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
13 minutes ago
- Business Insider
Billionaire Jeff Greene predicts house prices will soar once rates fall — and warns the US faces a 'downward spiral'
Interest rates are holding back a "huge boom" in the housing market, billionaire real estate developer Jeff Greene told Business Insider. In a wide-ranging interview, the Florida-based property tycoon said that prospective home buyers and sellers were "waiting for rates to come down." The annual interest on a 10-year, fixed-rate mortgage is still close to 7%, a sharp increase from below 3% four years ago. Federal Reserve Chair Jerome Powell said earlier this month that tariff-related uncertainty was the main reason the central bank hadn't cut rates since December. Mortgage rates closely track the Fed's benchmark rate. "If rates come down, we'll have a huge boom in housing prices," Greene told BI. A reduction in rates would likely result in more houses on the market, as homeowners who took out long-term mortgages at low rates would then be willing to refinance and move home, Greene said. "People have locked in loans for any number of years into the future, and so they're not going to give up those houses" before rates fall, he said. Increased supply could help first-time buyers get on the housing ladder, Greene said. It's "always been difficult" for young people to buy a home as they're competing against older people with deeper pockets, he said, but it's "particularly hard now" when rates are high and there are fewer homes for sale. A 'downward spiral' Greene said that federal spending, quantitative easing, low interest rates, and other forms of government stimulus have underpinned US economic growth for decades. "The economy's been running on printed money for a long time; it's not a secret," he said. "We've just printed money and given it to people." President Donald Trump's recently passed " Big Beautiful Bill" is likely to "keep the party going" and stave off an economic slowdown, Greene said. Greene said Trump struck him as someone who would negotiate deals so his tariffs wouldn't cause " huge dislocations in the economy." So far, the market seems to agree, and that outlook likely explains why stocks are at record highs, Greene said. But he warned about the rising national debt, and the US government's growing interest costs. "We've just kicked the can down the road for however many more years," he said. "You can drive 130 miles an hour down the road and have no accident, but at some point, somebody's going to pull out in front of you and you're going to die," he added. Greene also said that "throwing our immigrants out of the country" was unwise when America has an ageing population, with an increasing proportion of people living on Social Security. "We're kind of in a downward spiral," Greene said of the demographic challenges and mounting debt.
Business Wire
15 minutes ago
- Business Wire
NetCE Launches All Access Premium, Expanding Live CE Options to Mental Health Professionals
ROSEVILLE, Calif.--(BUSINESS WIRE)-- NetCE, a leader in continuing education (CE) for nurses, physicians, and mental health professionals, announces the launch of All Access Premium, an innovative continuing education offering designed specifically for mental health professionals. This comprehensive plan combines unlimited self-paced courses and live CE webinars into a seamless learning experience. We want professionals to have a world of learning at their fingertips, and to complete CE at their own pace, in a format they choose. Share 'Whether you're a social worker needing ethics and cultural competence hours, a professional licensed in multiple states who wants a one-stop CE solution, a therapist in New York or other states requiring live CE, or a behavioral health team looking to centralize staff learning needs, we offer one place for all professional learning needs,' said Diana Nicoletti, Senior Marketing Manager of Healthcare at NetCE. 'We created this product offering to reinforce our commitment to meeting the evolving needs of mental health professionals by expanding access to relevant, evidence-based, and state-approved education in both self-study and live formats. We want professionals to have a world of learning at their fingertips, and to complete CE at their own pace, in a format they choose.' Key features of NetCE's All Access Premium include: Unlimited access to more than 20 new live CE webinars each month. Coverage of live, ethics, cultural competence, and clinical CE requirements. +1000 board approved hours and +160 online courses, including live and homestudy learning. Instant certificates and mobile-friendly course access. Accreditation by leading bodies, including ASWB, APA, NBCC, and NAADAC. 'We want to eliminate the need for professionals to piece together live CE hours across multiple providers, and our new learning offering streamlines compliance and reduces cost and administrative burdens,' continued Nicoletti. NetCE's All Access Premium is available immediately. For more details or to explore NetCE's live webinar schedule, please visit: About NetCE: With over 30 years as an industry leader, NetCE provides healthcare professionals with evidence-based, accredited continuing education. NetCE's extensive course library, created by highly credentialed authors, supports professionals in maintaining licensure, enhancing clinical skills, and ensuring compliance. NetCE remains committed to delivering high-quality, accessible continuing education that promotes clinical excellence.
Miami Herald
15 minutes ago
- Miami Herald
Heading to Key West but don't want to drive? Spirit starting FLL flights
Long-time low-cost carrier Spirit Airlines is adding a destination to paradise as it continues the journey to remake itself. The Broward-based airline known for bright yellow planes will offer year-round flights between Fort Lauderdale-Hollywood International Airport and Key West International Airport for the first time. On Nov. 6, Spirit will launch four weekly flights, on Monday, Thursday, Friday and Sunday. Daily flights will begin on Dec. 18. Fares start at $79 one-way for trips booked by Nov. 19. Tickets are now available on the airline's website. Spirit is betting on a route that brings together two of the Sunshine State's most popular locales. Fort Lauderdale boasts popular beaches, a renovated pier, growing airport, booming port and influx of youth. The Florida Keys continue to see sky-high demand from tourists all over the world. While Miami — the city and its hotels — was shut out of the 2025 World's Best issue of Travel + Leisure, the Florida Keys ranked eighth among best islands in the continental United States. 'Spirit Airlines entering the Key West market this November is fantastic news for our passengers near and far,' Richard Strickland, executive director of airports at Key West International Airport, said in a statement. 'We welcome this addition to our selection of carriers and greatly anticipate access to Spirit's expansive network of destinations.' Key West will be the eighth destination in Florida that Spirit serves. Fort Myers, Miami, Orlando, Pensacola, Tampa and West Palm Beach are the others, along with Fort Lauderdale. The $79 one-way fares are subject to a 21-day advance purchase, valid for booking July 22 through Nov. 19, 2025, and travel from Nov. 6 through Dec. 17, 2025, the airline said. Blackout dates are Nov. 20 to Dec. 2, 2025. The Key West service comes after Spirit announced in July new direct flights between FLL and Macon, Georgia. The airline will have two flights a week beginning Oct. 16, starting at $49.99 one way. Macon is home to the Allman Brothers and Luther Williams Field, the baseball stadium used in '42,' the film about Jackie Robinson's life. A new Spirit Airlines? Beyond tourist attractions, the new flights will also give travelers an early glimpse of the new, slightly more upscale Spirit. In June, the airline started installing a section of seats — seven rows near the front — that have four additional inches of legroom, a total to 32 inches. The majority of its fleet is expected to have this feature by the end of July and all planes will in 2026. Spirit is also getting rid of its middle seats in the premium section. Flights in July are the first ones that offer the new perks. The moves come as Spirit is looking to carve out a market segment in a competitive market following several tough years. It's now taking on the bigger players with its premium offerings. In April, a new president and CEO, Dave Davis, took over. He replaced longtime President and CEO Ted Christie, who resigned April 7 after successfully leading the company through restructuring. On Feb. 20, the U.S. Bankruptcy Court for the Southern District of New York approved the carrier's plan to continue operating as a business, and cleared bankruptcy shortly after. Davis came from Sun Country Airlines, where he was president and chief financial officer and a member of its board of directors since December 2019. He was credited with helping make it one of the most profitable airlines in the U.S., outperforming Spirit and Frontier. Can new cabin names help? Travelers to Key West will also get a chance to try out Spirit's new cabin names that debuted in June: Spirit First (formerly Go Big) ▪ Big front seat/extra legroom ▪ Carry-on and first checked bag free ▪ No change or cancel fees ▪ Priority check-in and boarding ▪ Reserved overhead bin space ▪ Complimentary snacks and drinks ▪ Wi-Fi Premium Economy (formerly Go Comfy) ▪ Extra legroom ▪ No middle seat ▪ One carry-on bag free ▪ No change or cancel fees ▪ Priority boarding ▪ Reserved overhead bin space Value (formerly Go) ▪ One carry-on bag free ▪ Seat selection costs extra ▪ Checked bags purchased separately
